Elicio Therapeutics Announces Opening Of 20-Patient Investigator-Initiated Phase 1 Trial Of ELI-002 7P With Chemotherapy, Anti-PD1 In Neoadjuvant Pancreatic Cancer At Memorial Sloan Kettering
Share
Why It Matters
A cancer research hospital is testing a new medicine (ELI-002) mixed with two other treatments on 20 pancreatic cancer patients to see if it works safely. Watch this company's updates on whether the trial goes well, since positive results could show the medicine has promise.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.